Zürcher Nachrichten - Trump’s Crackdown: Lives/Risk

EUR -
AED 4.293743
AFN 80.911162
ALL 97.783064
AMD 448.784581
ANG 2.092139
AOA 1071.963126
ARS 1468.362845
AUD 1.77632
AWG 2.107102
AZN 1.987413
BAM 1.954862
BBD 2.359767
BDT 142.111786
BGN 1.954862
BHD 0.440589
BIF 3482.228512
BMD 1.168989
BND 1.495482
BOB 8.093115
BRL 6.509626
BSD 1.168739
BTN 100.189908
BWP 15.60351
BYN 3.824664
BYR 22912.182033
BZD 2.347573
CAD 1.599603
CDF 3373.701668
CHF 0.930825
CLF 0.028933
CLP 1110.277061
CNY 8.379955
CNH 8.383708
COP 4691.643348
CRC 589.417077
CUC 1.168989
CUP 30.978205
CVE 110.212098
CZK 24.663208
DJF 208.120101
DKK 7.461891
DOP 70.376219
DZD 151.699184
EGP 57.882959
ERN 17.534833
ETB 161.015012
FJD 2.621165
FKP 0.865556
GBP 0.865806
GEL 3.167949
GGP 0.865556
GHS 12.154166
GIP 0.865556
GMD 83.583861
GNF 10140.132683
GTQ 8.977691
GYD 244.512633
HKD 9.176393
HNL 30.572325
HRK 7.54056
HTG 153.396369
HUF 400.094038
IDR 18971.520521
ILS 3.893322
IMP 0.865556
INR 100.329058
IQD 1530.965129
IRR 49229.041804
ISK 142.394872
JEP 0.865556
JMD 186.890292
JOD 0.828888
JPY 171.996813
KES 150.998626
KGS 102.228303
KHR 4685.750815
KMF 492.319316
KPW 1052.089992
KRW 1608.983375
KWD 0.357465
KYD 0.973933
KZT 610.636891
LAK 25186.910152
LBP 104715.635948
LKR 351.461297
LRD 234.327522
LSL 20.840197
LTL 3.45172
LVL 0.70711
LYD 6.313969
MAD 10.526647
MDL 19.786502
MGA 5177.514766
MKD 61.505477
MMK 2454.33277
MNT 4192.162352
MOP 9.449864
MRU 46.490684
MUR 53.141857
MVR 17.997683
MWK 2026.527256
MXN 21.809595
MYR 4.969362
MZN 74.768303
NAD 20.840197
NGN 1788.891847
NIO 43.009355
NOK 11.84101
NPR 160.304053
NZD 1.944502
OMR 0.449474
PAB 1.168739
PEN 4.144211
PGK 4.831681
PHP 66.026824
PKR 332.349471
PLN 4.264877
PYG 9057.65228
QAR 4.260655
RON 5.077849
RSD 117.093794
RUB 91.26865
RWF 1688.789372
SAR 4.384296
SBD 9.733571
SCR 16.480089
SDG 701.971099
SEK 11.17973
SGD 1.496323
SHP 0.918642
SLE 26.297188
SLL 24513.116917
SOS 667.879414
SRD 43.495148
STD 24195.709621
SVC 10.226091
SYP 15199.024107
SZL 20.846993
THB 37.852156
TJS 11.295478
TMT 4.103151
TND 3.419359
TOP 2.737893
TRY 46.99955
TTD 7.940189
TWD 34.167149
TZS 3029.846208
UAH 48.828962
UGX 4188.989263
USD 1.168989
UYU 47.257316
UZS 14765.912285
VES 133.578629
VND 30527.560087
VUV 139.867093
WST 3.045814
XAF 655.642288
XAG 0.030335
XAU 0.000347
XCD 3.159251
XDR 0.815409
XOF 655.642288
XPF 119.331742
YER 282.719428
ZAR 20.971543
ZMK 10522.306496
ZMW 27.055013
ZWL 376.413942
  • CMSC

    0.0900

    22.314

    +0.4%

  • CMSD

    0.0250

    22.285

    +0.11%

  • RBGPF

    0.0000

    69.04

    0%

  • SCS

    0.0400

    10.74

    +0.37%

  • RELX

    0.0300

    53

    +0.06%

  • RIO

    -0.1400

    59.33

    -0.24%

  • GSK

    0.1300

    41.45

    +0.31%

  • NGG

    0.2700

    71.48

    +0.38%

  • BP

    0.1750

    30.4

    +0.58%

  • BTI

    0.7150

    48.215

    +1.48%

  • BCC

    0.7900

    91.02

    +0.87%

  • JRI

    0.0200

    13.13

    +0.15%

  • VOD

    0.0100

    9.85

    +0.1%

  • BCE

    -0.0600

    22.445

    -0.27%

  • RYCEF

    0.1000

    12

    +0.83%

  • AZN

    -0.1200

    73.71

    -0.16%


Trump’s Crackdown: Lives/Risk




In a dramatic push to tackle the skyrocketing cost of prescription drugs in the United States, President Donald Trump has taken decisive action against the pharmaceutical industry. With the stroke of a pen, he signed an executive order designed to slash drug prices, promising relief for millions of Americans burdened by exorbitant healthcare costs. However, this bold move has sparked fierce debate, with critics warning that the consequences could be catastrophic—potentially costing millions of lives due to drug shortages and stifled innovation.

Trump’s Plan to Lower Drug Prices
The executive order, enacted on May 12, 2025, seeks to align U.S. drug prices with those in other developed nations, where medications often cost a fraction of what Americans pay. Trump has long criticized the pharmaceutical industry for what he calls unfair pricing practices, arguing that U.S. consumers have been overcharged for years. The order aims to reduce prices by 30% to 80%, targeting both brand-name and generic drugs. It relies on voluntary compliance from drug companies, with the threat of future regulations looming if they fail to cooperate. For many patients, this could mean significant savings on medications that currently drain their finances.

The Dark Side: Drug Shortages Loom
While the goal of affordability is laudable, the plan has raised red flags among healthcare experts and industry leaders. One major concern is the risk of drug shortages. The U.S. already faces periodic shortages of critical medications, such as those used in cancer treatments and epidurals. Forcing pharmaceutical companies to lower prices could make it unprofitable to produce certain drugs, particularly low-cost generics. If production slows or stops, hospitals and pharmacies could struggle to secure enough supply, leaving patients without access to life-saving treatments. The ripple effect could be devastating, especially for vulnerable populations like cancer patients and the elderly.

A Blow to Innovation
Beyond immediate supply issues, the executive order could deal a severe blow to pharmaceutical innovation. Developing new drugs is an expensive and risky endeavor, often costing billions of dollars and taking years of research. The U.S. market, with its higher drug prices, has long been a key source of revenue for this work. If that revenue shrinks, companies may cut back on research and development, slowing the creation of new treatments for diseases like Alzheimer’s, cancer, and rare genetic disorders. A healthcare economist recently cautioned that such a move could “delay breakthroughs that millions of patients are counting on,” trading short-term savings for long-term losses in medical progress.

Economic Fallout
The economic implications are equally troubling. The pharmaceutical industry employs thousands of Americans and drives significant investment in the U.S. economy. Lower prices could lead to job cuts and reduced funding for new projects. One major drug company has already hinted at rethinking its $50 billion investment in the U.S. if the order takes full effect. While consumers might save money at the pharmacy, the broader economy could suffer as a result.

The Case for Change
Despite these risks, supporters argue that action is overdue. Prescription drug prices in the U.S. are nearly three times higher than in other advanced countries, forcing many Americans to ration their medications or skip doses entirely. Lowering prices could save billions of dollars and improve access for those with chronic conditions like diabetes or heart disease. For these patients, Trump’s order represents a lifeline—a chance to afford the drugs they need to survive.

A High-Stakes Gamble
As the dust settles, the debate rages on. Will Trump’s crackdown on the pharmaceutical industry deliver on its promise of affordable healthcare, or will it unleash a cascade of unintended consequences? The order’s success hinges on cooperation from an industry reluctant to sacrifice profits, and its failure could leave patients paying the ultimate price. For now, the nation watches as this high-stakes gamble unfolds, with millions of lives in the balance.